Temozolomide Capsule
Product Images NDC 16571-820

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Temozolomide (NDC 16571-820). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100-mg (100 mg)

Temozolomide Capsules USP 100 mg oral capsules packaged in a container of 5 capsules. The label includes handling caution for its cytotoxic nature, emphasizes prescription use only, and lists Rising Pharma Holdings, Inc. as the labeler, with manufacturing in India. The label features storage instructions and a barcode.*

FDA Label Image

140-mg (140 mg)

Label for Temozolomide Capsules, USP 140 mg by Rising Pharma Holdings, Inc. The label specifies oral administration and contains 5 capsules. It includes warnings about cytotoxic agent handling, storage instructions at controlled room temperature, and manufacturing details indicating the product is made in India. The label also features the NDC 16571-819-51 and a barcode.*

FDA Label Image

180-mg (180 mg)

Label for Temozolomide Capsules, USP 180 mg by Rising Pharma Holdings, Inc. The oral capsules come in a 5-capsule pack. The label includes a caution for cytotoxic agent special handling, storage instructions, manufacturer details listing Rising Pharma Holdings, Inc. in New Jersey, and indicates the product is made in India.*

FDA Label Image

20-mg (20 mg)

Temozolomide Capsules, USP 20 mg oral capsules by Rising Pharma Holdings, Inc. The label includes a caution stating 'Cytotoxic agent-Special Handling.' The package contains 5 capsules. Additional storage and handling instructions are noted, including storage at controlled room temperature. The label features the national drug code (NDC) 16571-817-51 and mentions the product is manufactured in India.*

FDA Label Image

250-mg (250 mg)

Packaging label for Temozolomide Capsules, USP 250 mg by Rising Pharma Holdings, Inc. The label indicates oral administration, contains 5 capsules, and highlights special cytotoxic agent handling. It includes storage instructions, manufacturing details (Made in India), and a barcode.*

FDA Label Image

5-mg (5 mg)

Label for Temozolomide Capsules USP 5 mg by Rising Pharma Holdings, Inc. The label states it is for oral administration and includes a caution about cytotoxic agent special handling. The package contains 5 capsules. Manufacturing information notes the product is made in India and includes storage instructions and dosage advisory.*

FDA Label Image

Figure 1 (Figure 01)

A survival curve chart titled 'ITT Population: Overall Survival' showing probability on the vertical axis and time from randomization (months) on the horizontal axis up to 40 months. Two lines represent different groups: one labeled 'RT + TMZ' with higher survival probability over time, and a second labeled 'RT Only' with lower survival probability. Data includes hazard ratio (HR 0.63, 95% CI 0.52-0.75) and log-rank P-value <0.0001, indicating statistical comparison between groups.*

FDA Label Image

Structural Formula (Structural Formula)

Chemical structure of temozolomide, showing its molecular framework including nitrogen atoms, a methyl group, and an amide functional group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.